Profound Medical Inc. is a leader in developing customizable, incision-free therapies for prostate diseases. The company specializes in transurethral ultrasound ablation (TULSA) technology, providing a patient-centric, MRI-guided procedure that ensures precise and accurate treatment. This innovative technology is CE marked, Health Canada approved, and FDA cleared in the U. S. , demonstrating a strong commitment to safety and efficacy in treating localized prostate cancer and other prostate disease states. With over 67 peer-reviewed publications and 5-year clinical outcomes, Profound Medical emphasizes durable treatment results and patient well-being. Their TULSA procedure uses real-time MRI temperature monitoring, enabling precise tissue ablation and ensuring patient safety while treating a range of prostate conditions.